

# Navin Fluorine International

# BUY

# Top level exits a valid concern

# **Summary**

We attended the call held by Navin Fluorine International (NFIL) to update on the resignation of the CEO, Radhesh Welling. Vishad Mafatlal, the Chairman handled most of the queries. The search for a senior professional as a successor is underway and will be updated in due course. The management mentioned that all the top clients have been informed about this transition and all of the major capex is on track although there could be slight delays of a quarter or so. Although the management did attempt to assuage investor concerns by stating that major capex plans and client engagements stay on track, we believe that recent exits of the CDMO head and the CEO are valid concerns warranting a cut in target multiple. We maintain our BUY rating with a downward revised target price of Rs 4,625 at 40x FY25E (Earlier 45x) earnings.

# **Key Highlights and Investment Rationale**

- Capex and Client Engagements on Track: Management maintained that all of the 3 business verticals, Specialty Chemicals, HPP and CDMO have strong independent CEOs and are well equipped to navigate through this management transition. Major capex plans are on track but could face a slight delay owing to the current ongoings. Clients continue to engage deeply with the company and there is no pushback from them amid the backdrop of an uncertain macro. The company has strengthened the Board with the addition of Mr Sudhir Deo who has decades of rich experience in the chemical domain.
- Fortifying employee retention measures: The management has implemented tools such as ESOP schemes, training programs and healthy remuneration to strengthen employee retention. Smooth transition will be facilitated for the incoming CEO who is most likely to be an external candidate having strong technical and leadership attributes.

TP R	s4,625
CMP R	s3,823
Potential upside/downside	21%
Previous Rating	BUY

Price Performance (%)							
	-1m	-3m	-12m				
Absolute	(16.8)	(14.6)	(14.4)				
Rel to Sensex	(16.5)	(14.6)	(29.2)				

V/s Consensus		
EPS (Rs)	FY24E	FY25E
IDBI Capital	92	116
Consensus	91	127
% difference	1.0	(8.5)

# Key Stock Data

Bloomberg / Reuters	NFIL IN / NAFL.BO
Sector	Specialty Chemicals
Shares o/s (mn)	50
Market cap. (Rs mn)	189,545
3-m daily average val	ue (Rs mn) 34.7
52-week high / low	Rs4,922 / 3,729
Sensex / Nifty	65,226 / 19,436

Shareholding Pattern (%)	
Promoters	28.8
FII	18.5
DII	20.4
Public	32.3

### **Financial snapshot**

(Rs mn)

Year	FY21	FY22	FY23	FY24E	FY25E
Revenue	11,794	14,534	20,774	27,659	35,047
Change yoy, (%)	11	23	43	33	27
EBITDA	3,093	3,548	5,503	7,564	9,606
Change yoy, (%)	17	15	55	37	27
EBITDA Margin(%)	26.2	24.4	26.5	27.3	27.4
Adj.PAT	2,420	2,631	3,752	4,581	5,730
EPS (Rs)	49	53	76	92	116
Change yoy, (%)	(40.8)	8.7	42.6	22	25
PE(x)	79.0	72.7	51.0	42	33
Dividend Yield (%)	-	-	-	-	-
P/B (x)	11.7	10.4	8.7	7.4	6.2
RoE (%)	14.8	14.3	17.2	18	18
RoCE (%)	15.6	15.3	16	17	19

Source: IDBI Capital Research, Company

### **Jason Soans**

jason.soans@idbicapital.com +91-22-2217 1727

## Aayush Rathi

aayush.rathi@idbicapital.com +91-22-2217 1840



**Exhibit 1: Quarterly Snapshot (Consolidated)** 

Consolidated (Rs mn)	Q1FY24	Q1FY23	QoQ (%)	Q4FY23	QoQ%
Net Sales	4,912	3,975	23.6%	6,971	-29.5%
Expenditure	-3,769	-2,984	26.3%	-4,953	-23.9%
as % of sales	-77%	-61%	26.3%	-101%	
Consumption of RM	-2,027	-1,823	11.2%	-2,837	-28.6%
as % of sales	-41%	-37%	11.2%	-58%	
Employee Cost	-792	-507	56.3%	-730	8.6%
as % of sales	-16%	-10%	56.3%	-15%	
Other expenditure	-951	-654	45.3%	-1,387	-31.4%
as % of sales	-19%	-13%	45.3%	-28%	
EBITDA	1,142	991	15.2%	2,018	-43.4%
Depreciation	-213	-124	72.4%	-76	180.5%
EBIT	929	868	7.1%	1,942	-52.2%
Other Income	83	109	-23.9%	40	107.5%
Interest	-194	-3	6600.0%	-140	38.7%
Exceptional	0	0	-	0	
PBT	818	974	-16.0%	1,842	-55.6%
Total Tax	-202	-229	-11.7%	-478	-57.6%
Reported PAT	615	745	-17.4%	1,364	-54.9%
Discontinued Ops	0	0	-	0	NA
Adjusted PAT	615	745	-17.4%	1,364	-54.9%
Adjusted EPS	12	15	-17.4%	28	-54.9%
Margins (%)			YoY (bps)		QoQ (bps)
EBIDTA	23.3%	24.9%	(168)	28.9%	(569)
EBIT	18.9%	21.8%	(291)	27.9%	(894)
EBT	16.6%	24.5%	(785)	26.4%	(977)
PAT	12.5%	18.7%	(620)	19.6%	(703)
Effective Tax rate	-24.8%	-23.5%	(121)	-26.0%	120

Source: Company, IDBI Capital



**Exhibit 2: Quarterly Segmental Snapshot (Consolidated)** 

Segment Revenue( Rs mn)	Q1FY24	Q1FY23	QoQ (%)	Q4FY23	QoQ (%)
Speciality	2,300	1,760	31%	2,040	13%
НРР	1,690	1,520	11%	2,890	-42%
Crams	930	700	33%	2,030	-54%
Total	4920	3980		6960	

Source: Company, IDBI Capital



## **Conference call highlights:**

- Management Update: Radhesh Welling and Vishad Mafatlal will collaborate to support the company's operations till 15<sup>th</sup> December, 2023. Company's growth plans remain unchanged, and company has appointed Sudher Deo as an additional Director.
- **Key Customers:** Company's relationship with Honeywell continues to be built on mutual trust and consistent performance at all levels. Capital expenditure is on track, and there have been no changes or impacts from their major customers. Many of them are committed to future projects. Management mentioned that they have three capable CEOs in place and have multiple touch points with their international key accounts.
- **R & D growth trajectory:** R&D operations continue as before, and Navin will maintain its current course, as it has for the past 4 years.
- **Future Projects:** Projects in pipeline are progressing as planned, with no issues expected in their delivery. Future projects in specialty chemicals and CGMP4 are under evaluation and could be affected by macro challenges.
- Senior Management: Radhesh Welling was responsible for leading all teams, a role that Vishad Mafatlal will now take on. Company mentioned that they have a strong 2<sup>nd</sup> and 3<sup>rd</sup> line of leadership. The NRC Committee is specifically addressing HR-related issues.
- Candidate Requirements: The management is considering external candidates for the Managing Directors position. Execution Requirement remains vital, especially for large projects, and having deep technological and operational expertise is crucial.
- **Fund Raising:** Navin's future project discussions will continue, and they are planning for a fundraising effort to support their growth requirements. The approval for the QIP has already been obtained, and they aim to raise funds to accelerate their growth.
- Focus Areas: While the company has mentioned that other key senior roles are currently filled, the company's objective is to reduce attrition.



(Rs mn)

# **Financial Summary**

# Profit & Loss Account

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Net sales	10,616	11,794	14,534	20,774	27,659	35,047
Change (yoy, %)	6.6	11	23	43	33	27
Operating expenses	(7,981)	(8,701)	(10,986)	(15,271)	(20,095)	(25,441)
EBITDA	2,635	3,093	3,548	5,503	7,564	9,606
Change (yoy, %)	20.7	17	15	55	37	27
Margin (%)	24.8	26.2	24.4	26.5	27.3	27.4
Depreciation	(370)	(442)	(479)	(626)	(1,122)	(1,507)
EBIT	2,265	2,651	3,069	4,877	6,442	8,099
Interest paid	(20)	(18)	(19)	(275)	(520)	(671)
Other income	333	790	392	357	106	112
Pre-tax profit	2,578	3,578	3,442	4,959	6,028	7,540
Tax	1,436	(1,108)	(812)	(1,207)	(1,447)	(1,810)
Effective tax rate (%)	(55.7)	31.0	23.6	24.3	24.0	24.0
Minority Interest	72.2	104.7	(0.1)	(0.0)	-	-
Net profit	4,086	2,575	2,631	3,752	4,581	5,730
Exceptional items	-	155	-	-	-	-
Adjusted net profit	4,086	2,420	2,631	3,752	4,581	5,730
Change (yoy, %)	174.0	(41)	9	43	22	25
EPS	82.4	48.8	53.1	75.7	92.4	115.6
Dividend per sh	-	-	-	-	-	-
Dividend Payout (%)	-	-	-	-	-	-



Balance Sheet						(Rs mn)
Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Shareholders' funds	14,122	16,339	18,442	21,850	25,888	31,075
Share capital	99	99	99	99	99	99
Reserves & surplus	14,023	16,240	18,343	21,750	25,789	30,976
Total Debt	-	-	1,000	7,531	10,531	11,531
Other liabilities	391	616	1,574	8,229	11,229	12,229
Curr Liab & prov	1,800	2,841	3,577	5,615	7,476	9,473
Current liabilities	1,772	2,020	3,839	5,215	6,312	7,475
Provisions	28	42	54	80	80	80
Total liabilities	2,164	2,636	5,413	13,443	17,540	19,704
Total equity & liabilities	16,285	18,975	23,855	35,293	43,428	50,779
Net fixed assets	4,917	5,371	12,079	18,397	23,275	26,768
Investments	1,279	145	139	130	130	130
Other non-curr assets	2,312	1,511	1,444	2,104	2,104	2,104
Current assets	7,777	11,947	10,193	14,662	17,919	21,777
Inventories	1,579	1,804	2,575	4,681	6,214	7,873
Sundry Debtors	2,185	2,841	3,577	5,615	7,476	9,473
Cash and Bank	2,779	5,439	958	348	212	413
Loans and advances	45		5			-
Total assets	16,285	18,975	23,855	35,293	43,428	50,779



Cash Flow Statement						(Rs mn
Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Pre-tax profit	2,578	3,578	3,442	4,959	6,028	7,540
Depreciation	370	442	479	626	1,122	1,507
Tax paid	(462)	174	(781)	(1,098)	(1,447)	(1,810)
Chg in working capital	(706)	(760)	(1,093)	(5,307)	(2,596)	(2,794)
Other operating activities	(213)	(1,061)	(1,300)	184	520	671
Cash flow from operations (a)	1,566	2,373	748	(636)	3,627	5,115
Capital expenditure	(979)	(906)	(5,758)	(7,555)	(6,000)	(5,000)
Chg in investments	1,697	(2,772)	3,757	799	-	-
Other investing activities	134	1,307	278	200	-	-
Cash flow from investing (b)	851	(2,371)	(1,724)	(6,556)	(6,000)	(5,000)
Equity raised/(repaid)	-	-	-	-	-	-
Debt raised/(repaid)	(27)	11	1,020	7,442	3,300	1,300
Dividend (incl. tax)	(714)	(394)	(542)	(543)	(543)	(543)
Chg in monorities	-	-	-	-	-	-
Other financing activities	(68)	(67)	(63)	(320)	(520)	(671)
Cash flow from financing (c)	(809)	(451)	415	6,579	2,237	86
Net chg in cash (a+b+c)	1,609	(449)	(561)	(613)	(136)	201



# **Financial Ratios**

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
Book Value (Rs)	282.4	327	369	437	518	622
Adj EPS (Rs)	81.7	48.4	52.6	75.0	91.6	114.6
Adj EPS growth (%)	174.0	-41	9	43	22	25
EBITDA margin (%)	24.8	26.2	24.4	26.5	27.3	27.4
Pre-tax margin (%)	24.3	30.3	23.7	23.9	21.8	21.5
Net Debt/Equity (x)	-0.2	-0.3	0.0	0.3	0.4	0.4
ROCE (%)	15.6	16	15	16	17	19
ROE (%)	28.9	15	14	17	18	18
DuPont Analysis						
Asset turnover (x)	0.7	0.6	0.6	0.6	0.6	0.7
Leverage factor (x)	1.2	1.2	1.3	1.6	1.7	1.6
Net margin (%)	38.5	20.5	18.1	18.1	16.6	16.3
Working Capital & Liquidity ratio						
Inventory days	54	56	65	82	82	82
Receivable days	75	88	90	99	99	99
Payable days	45	45	49	58	59	59

# **Valuations**

Year-end: March	FY20	FY21	FY22	FY23	FY24E	FY25E
PER (x)	46.8	79.0	72.7	51.0	41.7	33.4
Price/Book value (x)	13.5	11.7	10.4	8.7	7.4	6.2
EV/Net sales (x)	-0.3	-0.5	0.0	0.3	0.4	0.3
EV/EBITDA (x)	-1.1	-1.8	0.0	1.3	1.4	1.2
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0

Source: Company; IDBI Capital Research





Dealing (91-22) 6836 1111 dealing@idbicapital.com

**Key to Ratings Stocks:** 

**BUY:** 15%+; **HOLD:** -5% to 15%; **SELL:** -5% and below.

IDBI Capital Markets & Securities Ltd.

**Equity Research Desk** 

6th Floor, IDBI Tower, WTC Complex, Cuffe Parade, Colaba, Mumbai – 400 005. Phones: (91-22) 2217 1700; Fax: (91-22) 2215 1787; Email: info@idbicapital.com

SEBI Registration: BSE & NSE (Cash & FO) - INZ000007237, NSDL - IN-DP-NSDL-12-96, Research - INH000002459, CIN - U65990MH1993GOI075578

Compliance Officer: Christina D'souza; Email: compliance@idbicapital.com; Telephone: (91-22) 2217 1907

#### Disclaimer

This report has been published by IDBI Capital Markets & Securities Ltd.(hereinafter referred to as "IDBI Capital") for private circulation. This report should not be reproduced or copied or made available to others. No person associated with IDBI Capital is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this report. The information contained herein is strictly confidential and meant for solely for the selected recipient and may not be altered in any way, transmitted to copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without the prior written consent of IDBI Capital.

Recipients may not receive this report at the same time as other recipients. IDBI Capital will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is from the public domain or sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be reliable upon as such. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be reliable upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Opinions expressed are current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis, the information discussed in this material, IDBI Capital, its directors, employees are under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent us from doing so.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

IDBI Capital, its directors and employees and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report.

This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behavior of investors or recipients or provide any investment/tax advice.

This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis.

Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital.

Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of IDBI Capital, its directors, officers, or employees.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IDBI Capital and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this report may come are required to inform themselves of and to observe such restriction.

E-mail is not a secure method of communication. IDBI Capital cannot accept responsibility for the accuracy or completeness of any e-mail message or any attachment(s).

This transmission could contain viruses, be corrupted, destroyed, incomplete, intercepted, lost or arrived late. IDBI Capital, its directors or employees or associates accept no liability for any damage caused, directly or indirectly, by this email.

### Navin Fluorine International | Company Update



#### **Analyst Disclosures**

We, Jason Soans and Aayush Rathi, hereby certify that the views expressed in this report accurately reflect our personal views about the subject companies and / or securities. We also certify that no part of my compensation were, are or would be directly or indirectly related to the specific recommendations or views expressed in this report. Principally, We will be responsible for the preparation of this research report and have taken reasonable care to achieve and maintain independence and objectivity in making any recommendations herein.

#### Other Disclosure

IDBI Capital Markets & Securities Ltd. (herein after referred to as "IDBI Capital") was incorporated in the year 1993 under Companies Act, 1956 and is a wholly owned subsidiary of IDBI Bank Limited. IDBI Capital is one of India's leading securities firm which offers a full suite of products and services to individual, institutional and corporate clients namely Stock broking (Institutional and Retail), Distribution of financial products, Merchant Banking, Corporate Advisory Services, Debt Arranging & Underwriting, Portfolio Manager Services and providing Depository Services. IDBI Capital is a registered trading and clearing member of BSE Ltd. (BSE) and National Stock Exchange of India Limited (NSE). IDBI Capital is also a SEBI registered Merchant Banker, Portfolio Manager and Research Analyst. IDBI Capital is also a SEBI registered depository participant with National Securities Depository Limited (NSDL) and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI).

IDBI Capital and its associates IDBI Bank Ltd. (Holding Company), IDBI Intech Ltd. (Fellow Subsidiary), IDBI Asset Management Ltd. (Fellow Subsidiary) and IDBI Trusteeship Services Ltd. (Fellow Subsidiary).

IDBI Group is a full-serviced banking, integrated investment banking, investment management, brokerage and financing group. Details in respect of which are available on www.idbicapital.com IDBI Capital along with its associates are leading underwriter of securities and participants in virtually all securities trading markets in India. We and our associates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department. Investors should assume that IDBI Capital and/or its associates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material. IDBI Capital generally prohibits its analysts, persons reporting to analysts, and their dependent family members having a financial conflict of interest in the securities or derivatives of any companies that the analysts cover. Additionally, IDBI Capital generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Directors of IDBI Capital and its associates may have interest in the Companies under recommendation in this report either as Director or shareholder. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to buy a

IDBI Capital hereby declares that our activities were neither suspended nor we have materially defaulted with any Stock Exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on IDBI Capital, for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time. IDBI Capital, its directors or employees or associates, may from time to time, have positions in, or options on, and buy and sell securities referred to herein. IDBI Capital or its associates, during the normal course of business, from time to time, may solicit from or perform investment banking or other services for any company mentioned in this document or their connected persons or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or their affiliate companies or act as advisor or lender / borrower to such company(ies)/associates companies or have other potential conflict of interest. This report may provide hyperlinks to other websites. Except to the extent to which the report refers to the websites of IDBI Capital, IDBI Capital states that it has not reviewed the linked site and takes no responsibility for the content contained in such other websites. Accessing such websites shall be at recipient's own risk. IDBI Capital encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. Accordingly, neither IDBI Capital or Research Analyst have any material conflict of interest at the time of publication of this report. We offer our research services to primarily institutional inve